World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
42570
World Ranking
8492
National Ranking
4383

Overview

David P. Ryan is affiliated with Harvard University in the United States and has a research focus centered primarily in the field of Medicine, with extensive work in Oncology. The subfields central to their research include Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research, and Molecular Biology.

Their research covers a diverse range of topics, with notable emphasis on:

  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Palliative Care and End-of-Life Issues

David P. Ryan has contributed to publications in several key venues widely recognized in the oncology and medical research communities. These include:

  • Journal of Clinical Oncology
  • Cancer Research
  • International Journal of Radiation Oncology*Biology*Physics
  • Annals of Surgery
  • The Oncologist

Frequent collaborators in their research network comprise:

  • Theodore S. Hong
  • Jeffrey W. Clark
  • Jill N. Allen
  • Aparna R. Parikh
  • Jennifer Y. Wo

Among their recent publications are several significant papers in high-impact journals, including:

  • Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study, 2020, The Lancet Oncology
  • Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment, 2022, Nature Genetics
  • Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer, 2021, Clinical Cancer Research
  • Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial, 2021, Nature Cancer
  • Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial, 2023, Nature Medicine

Best Publications

  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

    Christopher G Willett;Yves Boucher;Emmanuelle di Tomaso;Dan G Duda

  • The case for knowledge translation: shortening the journey from evidence to effect.

    Dave Davis;Mike Evans;Alex Jadad;Laure Perrier

  • Differentiating the pathologies of cerebral malaria by postmortem parasite counts.

    Terrie E Taylor;Wenjiang J Fu;Wenjiang J Fu;Richard A Carr;Richard O Whitten

  • Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

    Cristina R. Ferrone;Giovanni Marchegiani;Theodore S. Hong;David P. Ryan

  • Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial

    Jennifer S. Temel;Joseph A. Greer;Areej El-Jawahri;William F. Pirl

  • NCCN Clinical Practice Guidelines in Oncology: colon cancer.

    Engstrom Pf;Arnoletti Jp;Benson Ab rd;Chen Yj

  • Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

    Darrell R. Borger;Kenneth K. Tanabe;Kenneth C. Fan;Hector U. Lopez

  • Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

    Matthew H. Kulke;Heinz Josef Lenz;Neal J. Meropol;James Posey

  • Carcinoma of the anal canal.

    David P. Ryan;Carolyn C. Compton;Robert J. Mayer

  • Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors

    Matthew H. Kulke;Keith Stuart;Peter C. Enzinger;David P. Ryan

  • NCCN Clinical Practice Guidelines in Oncology: rectal cancer.

    Engstrom Pf;Arnoletti Jp;Benson Ab rd;Chen Yj

  • Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

    Andrew X. Zhu;Dushyant V. Sahani;Dan G. Duda;Emmanuelle di Tomaso

  • RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis

    Min Yu;David Tsai Ting;Shannon Stott;Ben Wittner

  • Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

    Andrew X. Zhu;Lawrence S. Blaszkowsky;David P. Ryan;Jeffrey W. Clark

  • Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer

    Ryan B. Corcoran;Chloe E. Atreya;Gerald S. Falchook;Eunice L. Kwak

  • Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial

    Janet E. Murphy;Jennifer Y. Wo;David P. Ryan;Wenqing Jiang

  • Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

    Lipika Goyal;Supriya K. Saha;Leah Y. Liu;Giulia Siravegna

  • Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.

    Jeffrey W. Clark;Joseph P. Eder;David Ryan;Chetan Lathia

  • Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

    Theodore S. Hong;Jennifer Y. Wo;Beow Y. Yeap;Edgar Ben-Josef

  • Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

    Ioannis T Konstantinidis;Andrew Louis Warshaw;Jill Allen;Lawrence Scott Blaszkowsky

Frequent Co-Authors

Jeffrey W. Clark
Jeffrey W. Clark Harvard University
Andrew X. Zhu
Andrew X. Zhu Harvard University
Cristina R. Ferrone
Cristina R. Ferrone Harvard University
Jeffrey A. Meyerhardt
Jeffrey A. Meyerhardt Harvard University
Keith D. Lillemoe
Keith D. Lillemoe Harvard University
Beow Y. Yeap
Beow Y. Yeap Harvard University
Christopher G. Willett
Christopher G. Willett Duke University
Matthew H. Kulke
Matthew H. Kulke Boston Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare degrees online offers flexibility and can be a cost-effective way to advance your career. Many students consider bridging programs, such as the cheapest rn to bsn online, to build on existing nursing credentials while managing work and family commitments. These pathways make the transition from an RN to a BSN both accessible and affordable.

For those considering advanced practice or leadership roles, pursuing an online phd programs nursing can open doors to research, teaching, and high-level administration. Equally, finding the cheapest bsn programs provides value and can speed up entry into higher-paying jobs.

If you have a non-nursing bachelor’s degree, the cheapest direct entry msn programs let you shift careers into advanced nursing roles with minimal time spent. As online options expand, researching program accreditation, affordability, and career prospects is key to ensuring your education supports long-term goals in the medical field.

Best Scientists Citing David P. Ryan

Trending Scientists